pepperprint

PEPperPRINT unveils cLIFT technology for advanced peptide microarray applications

German biotechnology company PEPperPRINT has launched its next-generation peptide microarray platform, cLIFT (combinatorial Laser-Induced Forward Transfer), marking a significant advancement in high-density peptide screening capabilities for clinical research and diagnostic applications.

noul lab

NOUL unveils AI-powered miLab microscopy platform transforming point-of-care diagnostics

South Korean MedTech innovator NOUL has launched miLab™, an automated digital microscopy platform that promises to revolutionise diagnostic accessibility by bringing laboratory-grade analysis directly to resource-constrained clinical settings worldwide.

Micronic Tube Reader DT520

Micronic launches high-speed tube reader for enhanced laboratory sample identification

Micronic has introduced the Tube Reader DT520, a next-generation scanning solution designed to revolutionise sample identification workflows in clinical laboratories and research facilities. The compact device delivers sub-second barcode reading capabilities across multiple tube formats, addressing critical efficiency demands in high-throughput laboratory environments.

Cherwell Redipor TwistLock

Cherwell introduces TwistLock plates for enhanced microbial monitoring security

UK-based cleanroom microbiology specialist Cherwell has launched a new range of prepared media plates featuring secure locking technology designed to strengthen contamination control and data integrity in pharmaceutical environmental monitoring programmes.

Evosep

Evosep launches Eno platform targeting next-generation proteomics workflows

Evosep has unveiled its latest separation technology, the Evosep Eno™, designed to advance high-throughput LC-MS proteomics for pharmaceutical and biotech applications. The announcement, made at the Annual Conference on Mass Spectrometry (ASMS) in Baltimore, positions the platform as a cornerstone technology for next-generation proteomics workflows.

Azenta

Breakthrough in laboratory sterilisation: Azenta unveils revolutionary electron-beam tube technology

Azenta Life Sciences has achieved a significant milestone in sterile sample storage with the launch of advanced electron-beam (E-beam) treated tubes, marking a major shift towards chemical-free sterilisation in clinical and research laboratories. This breakthrough technology addresses critical contamination challenges whilst delivering unprecedented surface treatment uniformity.

AdobeStock 1127000356

TQ Therapeutics secures strategic acquisition to accelerate automated cell therapy breakthrough

German biotechnology firm TQ Therapeutics GmbH has strategically acquired Juno Therapeutics GmbH, dramatically expanding capabilities for developing next-generation ultra-short extracorporeal cell and gene therapy systems that could transform patient access to personalised cellular treatments.

AdobeStock 192284014

Tagomics secures £860k grant to advance colorectal cancer detection platform

Tagomics Ltd has secured £860,000 in Innovate UK Biomedical Catalyst funding to develop a sophisticated diagnostic test for early colorectal cancer detection, forming part of a £1.2 million project that could transform cancer screening capabilities. The Cambridge-based biomarker discovery company will customise its proprietary Interlace platform to identify genetic and epigenetic mutations associated with colorectal […]

Scherm­afbeelding 2025 06 25 om 11.48.50

Roche partners with Broad Clinical Labs for neonatal genome sequencing initiative

Roche has announced a strategic collaboration with Broad Clinical Labs to develop clinical applications for its Sequencing by Expansion (SBX) technology, with an initial focus on whole genome sequencing for critically ill newborns and their biological parents. The partnership aims to establish genomic sequencing as routine clinical practice in neonatal intensive care units.

AdobeStock 268793304

SpliceBio breaks gene therapy packaging barriers with US$135 million Series B funding

SpliceBio has secured US$135 million in Series B funding to tackle one of gene therapy’s most persistent technical barriers: the packaging capacity limitations that have rendered many genetic diseases untreatable. The Barcelona-based company’s breakthrough protein splicing technology promises to unlock therapeutic potential for conditions caused by genes too large for conventional delivery systems.